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Background
During the past 10 years, programmable cerebrospinal
fluid (CSF) shunts (PVS) have increasingly replaced con-
ventional non-programmable shunts (NPVS). However,
previous studies are inconclusive to the comparative effec-
tiveness of the valve systems for the treatment of patients
with hydrocephalus.
Materials and methods
The authors collected computerized data for all patients
subjected to a CSF shunt insertion or revision except those
with brain tumours from the Patient Data Management
System and the Computer Information System of the Seat-
tle Children's Hospital from 1 January 2000 through 31
December 2008. Data collected included the patient's
diagnosis, birth date, details of the operation insertion
and components of revisions, valve type and location,
type and timing of prophylactic antibiotic administration,
time of day of the operation, duration of operation, pres-
ence of a trainee, incidence of shunt complications and
white blood cell (WBC) and red blood cell counts (RBC)
in the CSF obtained at the time of operation. Patients were
followed for a minimum of one year post-operatively and
statistical analysis was done using Vassar STATS® and Med-
Calc® which included Chi Square, Kaplan Meier Survival
Curves and multi-variant analysis.
Results
A total of 1,278 operations were analyzed that incorpo-
rated 450 valve (233 PVS & 217 NPVS) implantations
(166) or revisions (284) for 306 patients. Patients with a
PVS that were adjusted (≥ 6 mo after implantation) dem-
onstrated no significant difference to rate of non-valve
revision (X2 p = 0.63), infection(X2 p = 0.99), or overall
valve survival (KM p = 0.24) compared to patients with
NPVS. Complications leading to valve replacement of the
initial implantation occurred in 42% of NPVS and 45% of
PVS(X2 p = 0.89). By differentiating patients by their pre-
operative WBC (poly ≥ 3 or mono ≥ 50) and/or RBC ≥ 30
in the CSF (as indications for inflammation), revisions of
NPVS were significantly greater in valve survival rate than
the PVS (p = 0.002). No significant differences existed
between the two valve systems for reason of revision, loca-
tion, age of patient, time of day, duration of the operation
type of antibiotic used or time of administration or pres-
ence of trainee.
Conclusion
This study provides a new rational based upon using pre-
operative WBC and RBC counts in the CSF to compare the
effectiveness between a PVS and a NPVS. As there is a
greater complexity involved with a PVS, it is likely that the
chance of occlusion of the valve increases which leads to
a lower rate of survival compared to the NPVS.
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